The immune checkpoint analysis indicated that gastric cancer patients with upregulated GGT5 expression showed a higher TIDE score and expression of CD274, CTLA4, HAVCR2, LAG3, PDCD1, PDCD1LG2, and TIGIT than patients in the GGT5-low expression group. Here, GGT5 is linked to gastric cancer.